Here’s what you need to know about BioAge’s IPO. BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm based in ...

BioAge Labs (NASDAQ:BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Shares of BioAge (BIOA ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

BioAge Labs Inc., which has turned its aging diseases ... The Richmond, California company, which first divulged its IPO plans in a Sept. 3 filing with the Securities and Exchange Commission ...

In that vein, there's a biotech stock called BioAge Labs (NASDAQ: BIOA) that just wrapped up its initial public offering (IPO) and is aiming to compete in the same areas as Lilly, as well as one ...

s IPO, will be sufficient to fund operations and capital expenses into 2029. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for ...

Well, a little-known biopharmaceutical company called BioAge Labs (NASDAQ: BIOA) is looking to bring a new spin to the weight loss space, and it just completed its initial public offering (IPO).

Portfolio Company Update: BioAge Labs completes $198 million IPO RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...